Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China.
{"title":"Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China.","authors":"Hongye Gao, Jiali Wang, Zhuoxin Zhang, Yannan Jia, Wenbin Cao, Yawei Zheng, Xiaolei Pei, Weihua Zhai, Rongli Zhang, Xin Chen, Qiaoling Ma, Jialin Wei, Donglin Yang, Aiming Pang, Yi He, Sizhou Feng, Hao Zhang, Xin Du, Yao Liu, Dehui Zou, Xianmin Song, Erlie Jiang","doi":"10.1007/s00277-025-06407-w","DOIUrl":null,"url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potentially curative treatment for peripheral T-cell lymphoma (PTCL), but the optimal conditioning regimen, particularly the use of total body irradiation (TBI), remains debated. To address this, we investigated outcomes from a cohort of 408 PTCL patients who underwent HSCT across five qualified medical centers in China. Focusing on a subset of 50 patients who received myeloablative conditioning prior to allo-HSCT, we compared outcomes between TBI-based (n = 28) and busulfan-based non-TBI (n = 22) regimens. Our analysis revealed comparable engraftment kinetics, incidence of acute and chronic graft-versus-host disease (GVHD), and overall survival (OS) between the TBI and non-TBI groups. These findings persisted even after propensity score matching (PSM) adjustment. Notably, at a median follow-up of 32.5 months, TBI conditioning was not identified as an independent risk factor for OS, progression-free survival (PFS), cumulative incidence of relapse, or non-relapse mortality. Importantly, non-TBI regimens demonstrated non-inferior OS and PFS compared to TBI, even in high-risk subgroups, including those with multiple prior treatments, elevated prognostic scores, or aggressive histology. Our findings suggest that non-TBI conditioning regimens represent a viable alternative for PTCL patients undergoing allo-HSCT, potentially offering comparable efficacy with reduced toxicity. Larger-scale studies are warranted to validate these findings.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3459-3468"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283884/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06407-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potentially curative treatment for peripheral T-cell lymphoma (PTCL), but the optimal conditioning regimen, particularly the use of total body irradiation (TBI), remains debated. To address this, we investigated outcomes from a cohort of 408 PTCL patients who underwent HSCT across five qualified medical centers in China. Focusing on a subset of 50 patients who received myeloablative conditioning prior to allo-HSCT, we compared outcomes between TBI-based (n = 28) and busulfan-based non-TBI (n = 22) regimens. Our analysis revealed comparable engraftment kinetics, incidence of acute and chronic graft-versus-host disease (GVHD), and overall survival (OS) between the TBI and non-TBI groups. These findings persisted even after propensity score matching (PSM) adjustment. Notably, at a median follow-up of 32.5 months, TBI conditioning was not identified as an independent risk factor for OS, progression-free survival (PFS), cumulative incidence of relapse, or non-relapse mortality. Importantly, non-TBI regimens demonstrated non-inferior OS and PFS compared to TBI, even in high-risk subgroups, including those with multiple prior treatments, elevated prognostic scores, or aggressive histology. Our findings suggest that non-TBI conditioning regimens represent a viable alternative for PTCL patients undergoing allo-HSCT, potentially offering comparable efficacy with reduced toxicity. Larger-scale studies are warranted to validate these findings.
期刊介绍:
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.